CN101578276A - 包含(-)-△9-反式-四氢大麻酚的组合物 - Google Patents

包含(-)-△9-反式-四氢大麻酚的组合物 Download PDF

Info

Publication number
CN101578276A
CN101578276A CNA2007800495962A CN200780049596A CN101578276A CN 101578276 A CN101578276 A CN 101578276A CN A2007800495962 A CNA2007800495962 A CN A2007800495962A CN 200780049596 A CN200780049596 A CN 200780049596A CN 101578276 A CN101578276 A CN 101578276A
Authority
CN
China
Prior art keywords
acid
composition
tetrahydrocannabinol
trans
aforementioned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800495962A
Other languages
English (en)
Chinese (zh)
Inventor
R·罗西
L·J·西尔弗伯格
R·霍根
R·沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey PLC
Original Assignee
Johnson Matthey PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey PLC filed Critical Johnson Matthey PLC
Publication of CN101578276A publication Critical patent/CN101578276A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA2007800495962A 2006-11-10 2007-11-09 包含(-)-△9-反式-四氢大麻酚的组合物 Pending CN101578276A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/595,682 2006-11-10
US11/595,682 US8039509B2 (en) 2006-11-10 2006-11-10 Composition comprising (−)-Δ9-trans-tetrahydrocannabinol

Publications (1)

Publication Number Publication Date
CN101578276A true CN101578276A (zh) 2009-11-11

Family

ID=39149274

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800495962A Pending CN101578276A (zh) 2006-11-10 2007-11-09 包含(-)-△9-反式-四氢大麻酚的组合物

Country Status (9)

Country Link
US (4) US8039509B2 (enExample)
EP (1) EP2086954B1 (enExample)
JP (1) JP5453096B2 (enExample)
CN (1) CN101578276A (enExample)
AU (1) AU2007316584B2 (enExample)
CA (1) CA2669021A1 (enExample)
IL (1) IL198651A (enExample)
MX (1) MX2009005003A (enExample)
WO (1) WO2008055992A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980940B2 (en) 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
EP2642982A2 (en) * 2010-11-22 2013-10-02 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
DE102012105063C5 (de) * 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
USD772284S1 (en) * 2014-09-01 2016-11-22 Apple Inc. Display screen or portion thereof with a set of graphical user interfaces
JP6676062B2 (ja) 2014-11-03 2020-04-08 ラモト アト テルーアビブ ユニバーシティー リミテッド 認知低下を処置するための方法
USD776682S1 (en) * 2015-09-04 2017-01-17 Salesforce.Com, Inc. Display screen or portion thereof with animated graphical user interface
USD801377S1 (en) * 2015-09-28 2017-10-31 ProductionPro LLC Display panel with transitional graphical user interface
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
CA3072768C (en) 2017-08-27 2024-06-11 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
CA3173494A1 (en) * 2020-09-24 2022-03-31 Michael Foster DAVIS Cannabinoid composition comprising at least 50% carrier

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
GB0112752D0 (en) 2001-05-25 2001-07-18 Johnson Matthey Plc Synthesis of cannabinoids
WO2003006010A1 (en) 2001-07-10 2003-01-23 Norton Healthcare Limited Aerosol formulations of δ8 tetrahydrocannabinol
WO2004000290A1 (en) 2002-06-22 2003-12-31 Norton Healthcare Limited Pharmaceutical composition
PT1542657E (pt) 2002-08-14 2012-02-29 Gw Pharma Ltd Formulações líquidas canabinóides para administração pela mucosa
US20040229939A1 (en) * 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
GB0329635D0 (en) 2003-12-23 2004-01-28 Johnson Matthey Plc Process for purifying trans-tetrahydrocannabinol
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
AU2005314021B2 (en) 2004-12-09 2010-02-11 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
ZA200802767B (en) * 2005-09-29 2009-09-30 Amr Technology Inc Process for production of delta-9-tetrahydrocannabinol
EP2046290A4 (en) 2006-08-04 2011-08-17 Insys Therapeutics Inc AQUEOUS DRONABINOL FORMULATIONS
EP1927582A1 (en) 2006-11-07 2008-06-04 Cytec Surface Specialties, S.A. Coatings for ceramic substrates
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
WO2009020666A1 (en) 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法

Also Published As

Publication number Publication date
US20120010279A1 (en) 2012-01-12
EP2086954A1 (en) 2009-08-12
US20130345299A1 (en) 2013-12-26
US8476312B2 (en) 2013-07-02
US20120322866A1 (en) 2012-12-20
US8039509B2 (en) 2011-10-18
AU2007316584A1 (en) 2008-05-15
AU2007316584B2 (en) 2013-02-14
JP5453096B2 (ja) 2014-03-26
MX2009005003A (es) 2009-06-12
US8906956B2 (en) 2014-12-09
WO2008055992A1 (en) 2008-05-15
JP2010509292A (ja) 2010-03-25
IL198651A0 (en) 2010-02-17
US20080139644A1 (en) 2008-06-12
IL198651A (en) 2014-09-30
CA2669021A1 (en) 2008-05-15
EP2086954B1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
EP2086954B1 (en) Composition comprising (-)-delta 9-trans-tetrahydrocannabinol
US9814775B2 (en) Method for making and storing stable cannabinoid compositions and method for treatment using such compositions
EP2642982A2 (en) Stable cannabinoid compositions and methods for making and storing them
CA2851999A1 (en) Solutions for oral administration comprising a piperazine-substituted benzothiophene
US10206925B2 (en) Topical formulations of PDE-4 inhibitors and their methods of use
WO2012085185A1 (en) Aqueous solution of ambroxol
KR20220058086A (ko) 항진균제를 포함하는 안정화된 조성물
KR102764741B1 (ko) 경구 전달용 조성물 및 투여 형태
US20260021128A1 (en) Composition including polyene antifungal drug and use thereof
WO2014075554A1 (zh) 含有西罗莫司酯化物的药物组合物及其制备方法
DE2850509A1 (de) Antidermatophytisches mittel und verwendung desselben zur bekaempfung von dermatomycosen
US7699987B2 (en) Stabilized formulation
WO2017037232A1 (en) Anidulafungin formulations
HK1137444A (en) Composition comprising (-)-△9-trans-tetrahydrocannabinol
EP2389931A1 (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
US11382871B2 (en) Pharmaceutical composition containing curcumin
KR100389671B1 (ko) 염산 테르비나핀을 함유하는 항진균제 외용 약제 조성물
CA2532110A1 (en) Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
HK1083596B (en) Intranasal formulation of rotigotine
NZ623523B2 (en) Solution for oral administration
CN1832725A (zh) 含有三嗪的生物活性组合物
HK1223568B (zh) 齐留通乳膏剂型的局部用抗炎症药学组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1137444

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20091111

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1137444

Country of ref document: HK